NovaBridge Biosciences (NBP)
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
NovaBridge Biosciences
NASDAQ:NBPHealthcare · Biotechnology
+3.01%$1.37
AH Close$1.42+3.65%vs close
AH Close$1.42+3.65%vs close
Mkt Cap$158.44M
Float64.44M
O/S115.65M
Inst Own21.3%
SI5.1%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$0
Net Income-$6.61M
Total Assets$37.24M
Free Cash Flow-$20.6M
Debt & Equity
Debt 1%
Equity 99%
Total Debt$438K
Total Equity$33.02M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in NBP's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$37.24M
Liabilities$4.23M
Accounts Receivable$256K
Accounts Payable$0
Inventory$0
PP&E (Net)$422K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Revenue | $0 | $0 | $4.49M | -$10.7M | $88.03M | $1.54B | $30M | $53.78M | $11.27M |
| YoY Growth | - | - | -141.9% | -112.2% | -94.3% | 5042.2% | -44.2% | 377.4% | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $46.43M | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $4.49M | -$10.7M | $41.59M | $1.54B | $30M | $53.78M | $11.56M |
| Gross Margin | - | - | 100.0% | 100.0% | 47.3% | 100.0% | 100.0% | 100.0% | 102.6% |
| Research and Development | $8.99M | $158.9M | $114.36M | $155.51M | $190.29M | $984.69M | $840.41M | $426.03M | $267.07M |
| Selling, General, and Administrative | $4.48M | $216.46M | $63.91M | $199.88M | $899.94M | $402.41M | $654.55M | $66.39M | $25.44M |
| Other | $0 | $0 | $337.38M | -$247 | $1.02B | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $13.48M | $375.36M | $515.65M | $355.38M | $2.11B | $1.39B | $1.49B | $492.42M | $292.51M |
| Operating Income (EBIT) | -$13.48M | -$375.36M | -$511.16M | -$366.08M | -$2.07B | $155.57M | -$1.46B | -$455.75M | -$273.89M |
| Operating Margin | - | - | -11395.1% | 3422.2% | -2353.1% | 10.1% | -4883.2% | -847.4% | -2431.2% |
| Interest Expense | $0 | $0 | $102K | $0 | $0 | $146K | $427K | $1.7M | $864K |
| Interest Income | $1.09M | $54.64M | $7.3M | $4.95M | $21.33M | $3.71M | $4.37M | $668K | $131K |
| Other Income (Expense) | $848K | $12.63M | -$954.53M | -$607.09M | -$260.73M | $327.58M | $13.02M | $38.99M | -$16.85M |
| Income Before Tax (EBT) | -$12.63M | -$362.73M | -$1.47B | -$973.17M | -$2.33B | $483.15M | -$1.45B | -$416.76M | -$290.74M |
| Income Tax Expense | $0 | $0 | -$1.26B | -$5.65M | -$495K | $12.23M | $0 | $1.72M | $0 |
| Net Income | -$6.61M | -$162.26M | -$1.47B | -$967.52M | -$2.33B | $470.92M | -$1.45B | -$402.83M | -$298.24M |
| Net Income Margin | - | - | -32674.0% | 9044.6% | -2648.7% | 30.5% | -4826.8% | -749.0% | -2647.4% |
| Supplementary Data | |||||||||
| EPS | -0.16 | -4.46 | -17.62 | -30.38 | -30.70 | 8.07 | -25.53 | -6.92 | -5.13 |
| Diluted EPS | -0.16 | -4.46 | -17.62 | -30.38 | -30.68 | 6.90 | -25.53 | -6.92 | -5.13 |
| Weighted Average OS | 41.64M | 81.19M | 83.19M | 82.52M | 75.93M | 68.25M | 58.17M | 58.17M | 58.17M |
| EBITDA | -$12.62M | -$368.25M | -$339.94M | -$356.6M | -$2.04B | $178.53M | -$192.07M | -$431.9M | -$279.32M |
| EBITDA Margin | - | - | -7578.0% | 3333.5% | -2317.1% | 11.6% | -640.2% | -803.1% | -2479.5% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Assets | |||||||||
| Current Assets | |||||||||
| Cash and Cash Equivalents | $30.11M | $498.24M | $291.51M | $3.21B | $552.8M | $4.76B | $1.14B | $1.59B | $307.93M |
| Short-Term Investments | $30K | $767.36M | $20.22M | $235.43M | $118.16M | $31.53M | $32M | $255.96M | $266.25M |
| Cash and Short-Term Investments | $30.14M | $1.27B | $311.73M | $3.45B | $670.96M | $4.79B | $1.17B | $1.84B | $574.17M |
| Accounts Receivable | $256K | $0 | $1.83M | $4.81M | $60.95M | $357.89M | $55.27M | $9.36M | $4.15M |
| Inventory | $0 | $0 | $0 | -$80.28M | $4.27M | $0 | -$55.87M | $0 | $0 |
| Other Current Assets | $0 | $15.84M | $15.68M | $242.96M | $0 | $192.92M | $191.56M | $108.1M | $110.71M |
| Total Current Assets | $31.1M | $1.29B | $329.91M | $3.63B | $750.18M | $5.34B | $1.36B | $2.04B | $691.59M |
| Long-Term Assets | |||||||||
| Property, Plant & Equipment Net | $422K | $27.72M | $5.55M | $123.97M | $24.87M | $40.27M | $46.5M | $27.66M | $22.34M |
| Goodwill | $0 | $0 | $0 | $162.57M | $25.51M | $162.57M | $162.57M | $162.57M | $162.57M |
| Intangible Assets | $0 | $0 | $0 | $118.89M | $18.77M | $120.44M | $148.84M | $148.84M | $148.84M |
| Long-Term Investments | $5.32M | $224.98M | $0 | $30.85M | $55.24M | $664.83M | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $402K | $9.96M | $33.46M | $10.91M | $4.18M | $2.01M | $18.33M | $0 | $0 |
| Total Long-Term Assets | $6.15M | $262.66M | $39.01M | $447.19M | $128.56M | $990.13M | $376.25M | $339.08M | $333.75M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $37.24M | $1.55B | $368.92M | $4.07B | $878.74M | $6.33B | $1.74B | $2.38B | $1.03B |
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Short-Term Debt | $0 | $0 | $0 | $2.75M | $0 | $0 | $50M | $80M | $99M |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $2.19M | $372K | $0 | $3.92M | $14.15M | $2.42M |
| Other Current Liabilities | $1.31M | $774K | $49.67M | $549.85M | $0 | $140.73M | $281.28M | $181.59M | $80.72M |
| Total Current Liabilities | $3.84M | $61.7M | $58.14M | $659.74M | $97.9M | $576.13M | $588.48M | $346.16M | $195.14M |
| Long-Term Liabilities | |||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $5.54M | $68.2M | $67.03M | $114.01M |
| Long-Term Unearned Revenue | $0 | $0 | $106K | $0 | $37.49M | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $73K | $520 | $64.83M | $373.53M | $15.2M | $124.98M | $3.11B | $2.92B | $1.02B |
| Total Long-Term Liabilities | $384K | $22.38M | $68.19M | $405.6M | $65.52M | $136.06M | $3.18B | $2.98B | $1.13B |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.23M | $84.08M | $126.34M | $1.07B | $163.42M | $712.19M | $3.77B | $3.33B | $1.33B |
| Stockholders' Equity | |||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $3.1B | $0 | $710.28M |
| Common Stock | $4K | $139K | $19K | $132K | $20K | $114K | $6K | $6K | $6K |
| Retained Earnings | -$190.47M | -$9.39B | -$1.26B | -$6.77B | -$683.21M | -$2.02B | -$2.49B | -$1.01B | -$357.86M |
| Comprehensive Income & Other | $5.94M | $243.66M | $39.77M | $216.72M | -$29.26M | -$50.79M | $70.13M | $59.38M | $5.69M |
| Other Stockholders' Equity | $223.48M | $10.85B | $1.51B | $9.77B | $1.4B | $7.65B | $3.56B | $59.38M | $768.34M |
| Total Equity | $33.02M | $1.47B | $242.58M | $3.01B | $715.33M | $5.63B | $1.07B | -$955.1M | $410.49M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $305.71M |
| Total Liabilities and Equity | $37.24M | $1.55B | $368.92M | $4.07B | $878.74M | $6.34B | $4.84B | $2.38B | $1.74B |
| Supplementary Data | |||||||||
| Total Debt | $438K | $28.33M | $3.89M | $38.29M | $17.64M | $19.14M | $132.5M | $147.03M | $213.01M |
| Net Debt | -$29.67M | -$469.9M | -$287.62M | -$3.18B | -$535.16M | -$4.74B | -$1B | -$1.44B | -$94.92M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Operating Activities | |||||||||
| Net Income | -$88.34M | -$362.72M | -$208.18M | -$2.51B | -$2.33B | $470.92M | -$1.45B | -$402.83M | -$298.24M |
| Depreciation & Amortization | $856K | $7.11M | $7.68M | $9.48M | $31.63M | $22.96M | $15.02M | $6.74M | $1.63M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | -$6.39M | -$75.03M | $8.53M |
| Stock-Based Compensation | $5.97M | -$14.23M | $10.26M | $357.15M | $608.61M | $493.46M | $366.89M | $3.52M | $7.04M |
| Changes in Working Capital: | |||||||||
| Accounts Receivable | $0 | $0 | $0 | $33.08M | $97.42M | -$130.5M | $11M | -$11M | $0 |
| Inventory | $0 | $0 | $0 | $27.24M | -$27.24M | $0 | $0 | $0 | $0 |
| Accounts Payable | $0 | $0 | $0 | $0 | $107.85M | $0 | $0 | $0 | $0 |
| Other Working Capital | $17.07M | -$20.52M | -$37.2M | $491.75M | $216.49M | -$110.14M | $173.79M | $158.08M | $25.04M |
| Total Working Capital Change | $17.07M | -$20.52M | -$37.2M | $552.06M | $394.52M | -$240.64M | $184.79M | $147.08M | $25.04M |
| Other Non-Cash Items | $43.84M | $6.06M | $154.58M | $485.82M | $323.69M | -$313.14M | $23.65M | $39.81M | $3.83M |
| Net Cash from Operating | -$20.6M | -$384.29M | -$72.85M | -$1.1B | -$973.09M | $433.56M | -$867.98M | -$280.7M | -$252.16M |
| Investing Activities | |||||||||
| Capital Expenditures | -$7K | -$350K | -$164K | -$45.83M | -$29.93M | -$8.01M | -$12.24M | -$14.41M | -$20.33M |
| Acquisitions | $0 | $0 | $0 | $0 | -$6M | -$257.65M | -$224.7M | $0 | $93.33M |
| Purchases of Investments | -$49.96M | -$1.79B | $0 | -$7.41B | -$10.17B | -$2.49B | -$134M | -$30M | -$369M |
| Sales of Investments | $154.88M | $801.66M | $0 | $7.91B | $9.48B | $2.5B | $358.7M | $53.91M | $138.33M |
| Other Investing Activities | $47K | $453K | -$107.47M | $26K | $0 | $52M | $224.7M | $0 | $0 |
| Net Cash from Investing | $104.97M | -$992.42M | -$107.63M | $458.38M | -$727.21M | -$201.9M | $212.46M | $9.5M | -$157.66M |
| Financing Activities | |||||||||
| Debt Repaid | - | - | - | - | - | $7.65M | -$183.04M | -$5.92M | -$446.31M |
| Common Stock Issuance | $61.91M | $0 | $0 | $0 | $0 | $543.5M | $0 | $0 | $0 |
| Common Stock Repurchases | $0 | -$2.45M | -$8.66M | -$3.08M | $0 | -$5.34M | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | -$5.28M | $0 | $0 |
| Other Financing Activities | -$4.19M | $0 | $408K | $60.86M | $593.92M | $2.91B | -$21.36M | $1.23B | $162.69M |
| Net Cash from Financing | $57.73M | -$2.44M | -$8.25M | $42.36M | $593.92M | $3.44B | $152.71M | $1.48B | $758.59M |
| Forex Effect | $276K | -$327.04M | $36.89M | $389.2M | -$128.77M | -$106.64M | $15.16M | $59.75M | -$132K |
| Net Change in Cash | $142.37M | -$1.71B | -$151.58M | -$212.86M | -$1.24B | $3.57B | -$487.65M | $1.27B | $348.63M |
| Supplementary Data | |||||||||
| Operating Cash Flow | -$20.6M | -$384.42M | -$72.85M | -$1.1B | -$973.09M | $433.56M | -$867.98M | -$280.7M | -$252.16M |
| Capital Expenditure | -$7K | -$350K | -$164K | -$45.83M | -$29.93M | -$8.01M | -$12.24M | -$14.41M | -$20.33M |
| Free Cash Flow | -$20.6M | -$384.77M | -$73.02M | -$1.15B | -$1B | $425.55M | -$880.22M | -$295.11M | -$272.48M |
| Cash at Beginning | $68.26M | $2.2B | $462.92M | $3.52B | $4.76B | $1.19B | $1.68B | $412.71M | $64.08M |
| Cash at End | $210.63M | $498.07M | $311.34M | $3.31B | $3.52B | $4.76B | $1.19B | $1.68B | $412.71M |